Targeting neuroendocrine abnormalities in Parkinson’s disease with exercise

Abstract

Parkinson's Disease (PD) is a prevalent and complex age-related neurodegenerative condition for which there are no disease-modifying treatments currently available. The pathophysiological process underlying PD remains incompletely understood but increasing evidence points to multiple system dysfunction. Interestingly, the past decade has produced evidence that exercise not only reduces signs and symptoms of PD but is also potentially neuroprotective. Characterizing the mechanistic pathways that are triggered by exercise and lead to positive outcomes will improve understanding of how to counter disease progression and symptomatology. In this review, we highlight how exercise regulates the neuroendocrine system, whose primary role is to respond to stress, maintain homeostasis and improve resilience to aging. We focus on a group of hormones -cortisol, melatonin, insulin, klotho, and vitamin D -that have been shown to associate with various non-motor symptoms of PD, such as mood, cognition, and sleep/circadian rhythm disorder. These hormones may represent important biomarkers to track in clinical trials evaluating effects of exercise in PD with the aim of providing evidence that patients can exert some behavioral-induced control over their disease.

1. Introduction

Parkinson’s disease (PD) is a neurodegenerative disorder involving progressive loss of nigrostriatal dopaminergic neurons. While motor symptoms such as tremor, bradykinesia, rigidity, and postural and gait disturbances are key in diagnosing PD, there are numerous non-motor symptoms (NMS) that associate with PD and add to its complexity in terms of patient experience and management. A wide range of interrelated cellular mechanisms are implicated in the pathogenesis of PD, including protein misfolding, mitochondrial dysfunction, oxidative stress, and neuroinflammation (Kalia and Lang, 2015). Search for disease-modifying treatments targeting putative pathogenic proteins has not been successful. Exercise has widespread symptom-related benefits in PD, improving motor and NMS of PD, and may be the only intervention available that can both slow disease progression and reduce the risk of developing PD (Sasco et al., 1992; Yang et al., 2015; Combs-Miller and Moore, 2019; Paul et al., 2019). While there are multiple mechanisms by which exercise may exert its benefits, here we describe the effects of exercise on neuroendocrine abnormalities associated with PD. We focus on a group of hormones – cortisol, melatonin, insulin, klotho, and vitamin D – specifically related to homeostasis and aging with relevance to PD.

2. Benefits of exercise in PD

The past decade has produced much evidence to support that exercise has neuroprotective benefits in PD (Zigmond et al., 2009; Tajiri et al., 2010; Tuon et al., 2012; Hou et al., 2017). Multiple mechanisms have been implicated including release of neurotrophic factors, improvements in mitochondrial function and oxidative stress, and anti-inflammatory effects (Tillerson et al., 2001; Cotman et al., 2007; Monteiro-Junior et al., 2015; Sujkowski et al., 2022). Acute exercise, or a single bout of exercise, initiates cellular pathways that transiently increase neurotransmitters, growth factors, and mediators of the “fight or flight” response, and increases cortical blood flow, oxygen availability, and glucose metabolism (El-Sayes et al., 2019). Regular exercise leads to chronic adaptations with upregulation of transcriptional and signaling cascades, cellular changes such as neurogenesis, synaptogenesis, gliogenesis and angiogenesis, as well as structural changes in the brain (El-Sayes et al., 2019). Studies in animal models of PD have shown that exercise ameliorates motor deterioration and loss of dopaminergic neurons (Tillerson et al., 2001; Petzinger et al., 2007; Zigmond et al., 2009).

In multiple prospective cohort studies, higher levels of physical activity have been associated with lower risk of developing PD (Sasco et al., 1992; Yang et al., 2015). Longitudinal cohort studies have also demonstrated that regular exercisers have a slower rate of change in motor, cognitive, and quality of life outcomes (Oguh et al., 2014; Combs-Miller and Moore, 2019; Paul et al., 2019). Amara et al. report that people with PD who have a higher score on Physical Activity Scale of the Elderly have a slower rate of progression of motor function decline, cognitive decline, and depression and anxiety (Amara et al., 2019). Despite these known benefits of exercise, the underlying mechanisms remain unclear. One important mechanism may be that exercise modulates hormones that maintain homeostasis and delay neuroendocrine aging.

3. Neuroendocrine abnormalities in PD and regulation by exercise

The neuroendocrine system encompasses both endocrine outputs from the nervous system, as well as peripheral hormones that act on the brain. It is a key system affected in PD that has important implications for pathogenesis and targets for disease modification. Since its primary function is to maintain homeostatic balance, PD-related abnormalities in the neuroendocrine system can lead to extensive downstream effects on stress, circadian rhythm, insulin resistance, and brain aging.

3.1. Cortisol

3.1.1. Cortisol dysregulation in PD

The hypothalamic–pituitary–adrenal (HPA) axis is a pivotal neuroendocrine axis that modulates physiological homeostasis, stress responsivity and circadian function. The hypothalamus secretes corticotrophin-releasing hormone, which stimulates the anterior pituitary to release adrenocorticotropic hormone (ACTH). This ultimately signals the adrenal glands to release cortisol, which has widespread effects on the brain, affecting mood, behavior, cognition, and programming of the stress response (Viho et al., 2019).

Increasing evidence points to HPA axis dysregulation in PD. Heightened activity with elevated ACTH and cortisol levels has been reported in people with PD (Stypula et al., 1996). Cortisol levels also appear to be persistently elevated in blood (Hartmann et al., 1997; Breen et al., 2014; Costa et al., 2019) and saliva (Djamshidian et al., 2011; Skogar et al., 2011) of PD patients. Additionally, cortisol levels increase with aging and chronic stress, both of which are risk factors for PD (Lupien et al., 2009, 2018; Moffat et al., 2020). Epidemiological studies have revealed that higher job demands and expectations (Sieurin et al., 2018) and higher number of exposures to stressful events (Vlajinac et al., 2013) associate with an increased risk of development of PD.

Changes in stress and thus changes in cortisol can affect diverse symptoms of PD. Stress modulates motor system function since most parts of the motor system express glucocorticoid receptors, the primary receptor for cortisol (Metz, 2007). In PD mouse models, chronic stress exposure worsens motor deficits, aggravates neurodegeneration of the nigrostriatal system, and completely blocks compensatory recovery of motor tasks (Smith et al., 2008). In people newly diagnosed with PD, higher cortisol levels have been linked with greater deterioration in motor function (Haglin and Backman, 2016). Cortisol levels have also been associated with severity of depression (Seifried et al., 2013), prevalence of anxiety and anhedonia (van den Heuvel et al., 2020) and increased risk-taking in individuals with PD who have impulse compulsive behavior (Djamshidian et al., 2011).

3.1.2. Acute and chronic effects of exercise on cortisol

Exercise acts both as a stressor and modifier of the neuroendocrine stress response (Hackney, 2006). Acute exercise, or single exercise session, activates the short-term stress response and increases salivary and plasma cortisol during the initial 30–60 min post-exercise (Wang et al., 2019; Dote-Montero et al., 2021). Moreover, Luger et al. have shown that this response appears to be directly proportional to the volume or intensity of exercise (Luger et al., 1987). An exercise intensity of 50–60% maximal oxygen uptake is the threshold before there is a change in cortisol, and this response amplifies when the intensity increases to 85%. In a study of elderly healthy men, cortisol released in response to acute vigorous exercise suppressed the subsequent cortisol response when presented with a psychosocial stressor, and this effect is dependent on exercise intensity (Caplin et al., 2021). Importantly, post-awakening salivary cortisol secretion and the cortical awakening response is significantly lower on the morning following an exercise session in healthy individuals (Anderson et al., 2023).

Chronic, or long-term, exercise training, defined as multiple sessions per week for duration ≥12 weeks in human studies, has different effects compared to acute exercise. Six months of high-intensity endurance exercise in women with mild cognitive impairment resulted in reduced plasma cortisol levels and improved executive cognitive function (Baker et al., 2010). A meta-analysis by Beserra et al. reports that in individuals with major depressive disorder, regular exercise is associated with decreased daytime cortisol levels but this is influenced by type of exercise and frequency (Beserra et al., 2018). Studies looking at the effects of exercise on cortisol levels in PD are sparse, but one study reports that 6 months of regular high-intensity treadmill exercise reduces cortisol secretion during the post-awakening period in people with PD (Smyth et al., 2019). Further studies are needed to clarify the acute and chronic effects of exercise on cortisol levels in individuals with PD and how this relates to motor and NMS of PD. Given initial studies showing an association between cortisol and mood, cognition, and motor burden in PD, it is possible that exercise-medicated regulation of cortisol may improve these symptoms.

3.2. Melatonin

3.2.1. Melatonin and circadian rhythm disruption in PD

Another key function of the neuroendocrine system is regulation of the circadian rhythm, orchestrated by the central biological clock – the suprachiasmatic nucleus (SCN). SCN is located within the hypothalamus and is attuned to the environmental 24 h cycle by projections from the retinohypothalamic tract, oscillators in peripheral tissues, and circulating neurotransmitters and hormones such as serotonin, cortisol, and melatonin (Saper et al., 2005; Dibner et al., 2010; Blume et al., 2019). SCN neurons adjust their circadian phase according to these photic and non-photic inputs and signal using humoral and autonomic nervous systems to the rest of the body. A key output pathway of the SCN is its projection to the pineal gland where melatonin is produced (Cajochen et al., 2003). Therefore, these input and output pathways are reciprocal. The neurohormone melatonin acts as a transmission signal to coordinate and stabilize the circadian rhythm and regulate hormone secretion, core temperature, cognition, and mood (Cardinali, 2021).

Increasing evidence points to circadian rhythm disruption being a key feature in PD, one that influences not just symptom expression but potentially also PD-associated neurodegeneration. Reduced SCN firing rate has been reported in PD mouse models, which may lead to overall decreased circadian output (Kudo et al., 2011). Breen et al. have reported hypothalamic volume loss and associated decreased melatonin output in people with PD (Breen et al., 2016). A cross-sectional study also confirmed significantly diminished amplitude and amount of melatonin secretion in individuals with PD compared to controls, which associated with excessive daytime sleepiness but not motor function (Videnovic et al., 2014). In a large cohort of newly diagnosed PD, the majority of participants showed abnormal sleep macro-architecture including increased sleep latency, reduced sleep efficiency, and reduced REM sleep, associating with lower circulating melatonin levels (Breen et al., 2014).

Accumulating evidence shows that melatonin has anti-apoptotic, anti-oxidant, anti-inflammatory, and free radical-scavenging properties that protect against mitochondrial dysfunction (Leon et al., 2004; Rodriguez et al., 2004; Esposito and Cuzzocrea, 2010; Singhal et al., 2011, 2012). An additional mechanism by which melatonin may exert its benefit is through stimulating autophagy and inhibiting aggregation of prion-like proteins such as α-synuclein that misfold and aggregate in PD (Jeong et al., 2012). Evidence for improvements in motor function have been observed with administration of 3-10 mg/kg of melatonin in multiple studies using rodent models of PD (Kim et al., 1998; Sharma et al., 2006; Gutierrez-Valdez et al., 2012; Zaitone et al., 2013). On the other hand, a study by Bassani et al. suggests that while administration of melatonin 10 mg/kg protects against dopaminergic loss and improves depression, it does not improve motor deficits in rats (Bassani et al., 2014).

In individuals with mild cognitive impairment, treatment with 3-9 mg of melatonin for 2 years has been shown to improve cognitive and depressive symptoms in addition to sleep (Jean-Louis et al., 1998; Furio et al., 2007; Cardinali et al., 2012). While 3–9 mg of melatonin improves sleep qualities and rapid eye movement (REM) sleep behavior disorder (RBD; Takeuchi et al., 2001; Medeiros et al., 2007), studies have failed to show an improvement in motor symptoms (Medeiros et al., 2007; Liguori et al., 2022). RBD appears in the prodromal phase of PD, preceding motor symptoms of PD by several years (Boeve et al., 2001; Iranzo et al., 2006; Tolosa et al., 2007). Studies have reported that >80% of individuals who initially developed RBD had progressed to develop PD, related synucleinopathy, or dementia within 10 years (Iranzo et al., 2013; Schenck et al., 2013). An interesting case report has described increase in dopamine transport density (as assessed by dopamine transporter scintigraphy) in an elderly male patient with RBD treated with 2 mg of melatonin daily (Kunz and Bes, 2017). After 6 months of treatment, his RBD disappeared. His dopamine transporter scan with binding ratios in the abnormal range before treatment showed improved binding ratios in the normal range 2 years after treatment with melatonin and remained normal even 4 years after the first scan. Although a case report provides only one patient’s response to melatonin therapy, it suggests that melatonin may have neuroprotective benefits, warranting further investigations.

3.2.2. Exercise regulates melatonin

There is growing interest in the use of exercise to synchronize the circadian rhythm, with studies showing that scheduled exercise can entrain the human sleep–wake rhythm. Vigorous wheel running exercise prevents the loss of rhythmicity induced from maintaining rats under constant light, and accelerates the emergence of a circadian pattern in rats moved to dim light (Lax et al., 1998). In healthy elderly men, a 3-month exercise training program induced a significant reduction in the fragmentation of their rest-phase rhythm (Van Someren et al., 1997). Exercise effects on improving the circadian rhythm clock are likely mediated by its effect on melatonin secretion. Exercise can have phase-shifting effects on melatonin secretion and lead to both acute and chronic increase in melatonin levels (Buxton et al., 1997). Exercise has also been shown to be beneficial in treatment of circadian rhythm disorders such as sleep, jet lag, and shift work disorder (Eastman et al., 1995; Shiota et al., 1996). Intensity and time of exercise also influences melatonin secretion, with melatonin levels increasing more with high-intensity exercise as compared to moderate-intensity exercise and morning exercise leading to a greater increase in melatonin at night compared to afternoon exercise (Kim and Kim, 2014; Carlson et al., 2019). Studies investigating whether exercise increases melatonin in people with PD are lacking. However, based on the known disruption in melatonin secretion in PD and the beneficial effects of melatonin administration in preclinical models of disease and in clinical trials of people with MCI and sleep disorders, exercise may be an essential way to restore melatonin levels and circadian rhythm in PD.

3.3. Insulin

3.3.1. Insulin resistance and PD

It is now well recognized that there is an association between type II diabetes mellitus and increased risk of developing PD (Cullinane et al., 2022). (Figure 1) In the periphery, insulin regulates glucose metabolism, but within the central nervous system, it has neuromodulatory, neuroprotective, and neurotrophic effects. The majority of insulin comes from pancreatic B-cells, and is transported across the blood–brain barrier; however insulin and the closely related insulin-like growth factor 1 (IGF-1) are also produced by pyramidal neurons in the cortex, hippocampus, and olfactory bulb (Ghasemi et al., 2013). Insulin receptors are abundantly found in the basal ganglia and substantia nigra (Figlewicz et al., 2003).

Insulin regulates dopaminergic transmission, maintenance of synapses, synaptic plasticity, and neuronal survival and growth (Chen et al., 2022). A marked loss of insulin receptor mRNA in the substantia nigra pars compacta and increased levels of insulin receptor phosphorylation, which deactivates insulin signaling, has been reported in PD (Moroo et al., 1994; Takahashi et al., 1996; Sekar and Taghibiglou, 2018). Moroo et al. have shown that in PD brains post mortem, there is almost total loss of insulin receptor-positive neurons in the substantia nigra while some dopaminergic neurons remain, suggesting that downregulation in the insulin receptor system may precede the death of dopaminergic neurons (Moroo et al., 1994). Both insulin deficiency and insulin resistance lead to decreased brain insulin signaling in PD and contribute to neuroinflammation, mitochondrial dysfunction, and oxidative stress (Cullinane et al., 2022). Induction of insulin signaling with IGF-1 and reversal of insulin resistance suppresses α-synuclein aggregation and toxicity (Kao, 2009).

In individuals with PD, insulin resistance associates with a more severe phenotype, accelerated disease progression, and increased risk of cognitive decline (Cereda et al., 2012; Kotagal et al., 2013; Malek et al., 2016; Mohamed Ibrahim et al., 2018). Population-based cohort studies have also shown that use of certain antidiabetic drugs (glitazones, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase inhibitors), associate with a lower risk of developing PD (Brakedal et al., 2017; Brauer et al., 2020; Cullinane et al., 2022). The glucagon-like peptide-1 receptor agonist–exenatide–is also being explored as a potential disease modifying agent in PD (Cardoso and Moreira, 2020; Mulvaney et al., 2020).

3.3.2. Exercise improves insulin sensitivity

Exercise has long been known to improve insulin sensitivity peripherally (Borghouts and Keizer, 2000; Sampath Kumar et al., 2019). In the brain, animal studies also point to exercise having a favorable impact on insulin signaling pathways (Park et al., 2005; Muller et al., 2011). In rodent models of insulin resistance and impairment in insulin receptor function in the hippocampus, treadmill exercise can rescue this decline in insulin signaling (Park et al., 2019). In rats with memory impairments, exercise raises insulin signaling in conjunction with improved cognitive function (Jeong et al., 2018).

In middle-aged sedentary individuals, exercise for 8 weeks was shown to increase brain insulin sensitivity following intranasal insulin administration (Kullmann et al., 2022). Honkala et al. demonstrated that sprint interval training, but not moderate-intensity continuous training, decreased insulin-stimulated glucose uptake in cortical gray matter and most brain regions in insulin-resistant, middle-aged adults (Honkala et al., 2018). Exercise also influences IGF-1 gene expression and protein levels in several brain regions, especially those involved in learning and cognition (Duzel et al., 2016). Exercise has been shown to induce increase in circulating IGF-1 in the periphery which can be transported through the blood–brain barrier into the brain (Schwarz et al., 1996). Further studies need to explore the effects of exercise on insulin sensitivity and IGF-1 levels in PD. Exercise-enhanced insulin signaling may be crucial in PD to counter the detrimental downstream effects of insulin resistance, such as neuroinflammation, mitochondrial dysfunction, and oxidative stress and a more severe PD phenotype.

3.4. Klotho

3.4.1. A role for longevity hormone klotho in PD

Klotho was discovered as a master aging regulator when deficiency of the klotho protein in mice was found to severely shorten lifespan and prompt signs of premature aging while overexpression of klotho increased lifespan by ~30% (Kurosu et al., 2005; Zeldich et al., 2014). Additionally, klotho-insufficient mice develop degeneration of mesencephalic dopaminergic neurons in substantia nigra and ventral tegmentum area (Kosakai et al., 2011). Human relevance for klotho in longevity is supported by studies demonstrating that klotho levels decline with aging (Yamazaki et al., 2010; Semba et al., 2011) and klotho genetic variants are associated with lifespan in multiple aging populations (Arking et al., 2002, 2005). Mechanistically, klotho has multifactorial actions–it suppresses insulin and Wnt signaling (Utsugi et al., 2000; Liu et al., 2007), regulates ion channel clustering and transport (Chang et al., 2005), modulates N-methyl-D-aspartate receptor (NMDAR) signaling (Dubal et al., 2014) and promotes fibroblast growth factor (FGF) function (Urakawa et al., 2006). Klotho linked with FGF23 is important for regulation of calcium, phosphate, and vitamin D homeostasis (Tsujikawa et al., 2003; Razzaque, 2009; Huang and Moe, 2011; Hum et al., 2017; Erben, 2018; Kuro, 2018). Klotho overexpression also inhibits insulin/IGF-1 signaling as a mechanism to extend life (Kurosu et al., 2005). While insulin resistance increases with aging and thus is generally unfavorable, klotho’s role in inhibiting the insulin/IGF-1 pathway is to decrease lipid overload since lipid-laden cells are vulnerable to lipid-induced programmed cell death (Unger, 2006).

Mounting evidence now links klotho with enhanced cognition. In mouse models of aging and Alzheimer’s disease, systemic elevation of klotho boosts cognitive function and enhances long-term potentiation (Dubal et al., 2014, 2015; Masso et al., 2018; Zeng et al., 2019). Recently, subcutaneous delivery of low but not high dose klotho was shown to enhance cognition in aged rhesus monkeys (Castner et al., 2023). In humans, carrying a genetic variant of KLOTHO or having higher levels of klotho has been associated with better cognition or decreased risk of dementia in aging and in Alzheimer’s disease (Dubal et al., 2014; Yokoyama et al., 2015; Belloy et al., 2020; Ali et al., 2022; Kundu et al., 2022).

In PD mouse models, peripherally delivered klotho has been shown to result in improvement in cognitive and motor behavior and enhanced synaptic plasticity (Leon et al., 2017). Furthermore, klotho overexpression or exogenous klotho administration protects dopaminergic neurons against oxidative injury and alleviates astrogliosis, apoptosis, and oxidative stress (Baluchnejadmojarad et al., 2017; Leon et al., 2017). Recently, lower levels of cerebrospinal fluid klotho were reported in individuals with PD compared to healthy controls and associated with greater motor burden of disease and greater Hoehn and Yahr stage of disability (Zimmermann et al., 2021). Since aging is a major risk factor for PD, further studies are needed to investigate if klotho associates with clinical symptoms of PD or disease progression.

3.4.2. Exercise upregulates klotho

Given the known beneficial effects of exercise on health and longevity, it is not surprising that exercise is associated with changes in aging regulator klotho. Higher levels of klotho associate with superior lower extremity strength and functioning in older adults (Crasto et al., 2012; Semba et al., 2016; Saghiv et al., 2017). Klotho levels also tend to be higher in exercise-trained individuals compared to their untrained counterparts (Saghiv et al., 2017). In healthy middle-aged adults, endurance, or resistance exercise boosts plasma klotho levels both acutely and chronically (Matsubara et al., 2014; Santos-Dias et al., 2017; Tan et al., 2018; Amaro-Gahete et al., 2019). When looking at the underlying mechanisms of exercise, Jin et al. demonstrated that irisin, an exercise-derived myokine, enhances mortality and cognition in mice after cerebral ischemia through upregulation of klotho (Jin et al., 2021). This positive effect of exercise and irisin is abolished in klotho-knockout mice (Jin et al., 2021). Exercise-induced upregulation of klotho in rodents has also been linked to decreased production of reactive oxygen species leading to decreased oxidative stress (Ji et al., 2018).

Additional studies are needed to examine the effects of exercise on klotho in people with PD. With increasing evidence for klotho’s impact on longevity, cognition, and neuroprotection, there is fervent interest in development of klotho-boosting therapeutics. Exercise may be one way to enhance klotho levels that may help with PD symptoms and progression.

3.5. Vitamin D

3.5.1. Multifunctional hormone vitamin D in PD

Vitamin D is a powerful neurosteroid that can pass the blood–brain barrier to play a significant role in the central nervous system. While in the periphery vitamin D is critical for bone metabolism and calcium regulation, its effects in the brain are vast. It plays a role in anti-inflammatory and anti-oxidant actions, intracellular calcium signaling, neurotransmitter release, and transcriptional regulation of >200 genes, including neurotrophins (Pignolo et al., 2022).

Vitamin D receptor concentration is richest in the substantia nigra and the hypothalamus (Eyles et al., 2005). Additionally, 1α-hydroxylase – the enzyme that converts vitamin D to its active form,1,25(OH)₂D₃ – is highly expressed in the substantia nigra, suggesting that vitamin D may be related to the pathogenesis of PD via loss of protection for vulnerable dopaminergic neurons in this brain region (Eyles et al., 2005). In their meta-analysis, Zhou et al. report that both 25-hydroxyvitamin D [25(OH)D] insufficiency (<30 ng/ml) and deficiency (<20 ng/mL) are significantly associated with an increased risk of PD (Zhou et al., 2019). A high prevalence (55–69%) of 25(OH)D deficiency has been noted in individuals with PD (Evatt et al., 2008, 2011). Higher vitamin D concentrations have also been shown to associate with better cognitive function and mood in individuals with PD (Peterson et al., 2013).

Peterson et al. demonstrate that treatment with vitamin D (30 mg/kg subcutaneously) in a rat model of PD attenuates behavioral deficits, decreases levels of oxidative stress and neuroinflammatory markers and prevents dopaminergic cell loss (Bayo-Olugbami et al., 2022). Administration of intraperitoneal vitamin D (1 μg/ml/kg per day) in rats has also been shown to reduce dopaminergic cell loss and increase expression of glial-derived neurotrophic factor (Sanchez et al., 2009). In a randomized, placebo-controlled trial, vitamin D supplementation at a dose of 1,200 international units per day for 12 months in PD participants with a certain vitamin D receptor genotype (Fok/CC) associated with better motor function, Hoehn & Yahr stage, and quality of life (Suzuki et al., 2013). Interestingly, the Fok/CC vitamin D receptor genotype has also previously been shown to be associated with less advanced cases of PD (Suzuki et al., 2012) and to have greater effects of vitamin D-dependent transcriptional activation as compared to the Fok/TT genotype. In another recent randomized placebo-controlled trial, Bytowoska et al. investigated the effects of vitamin D ranging in dose from 2,500 to 4,800 international units per day (based on body mass index) in patients with PD who had previously undergone deep brain stimulation surgery (Bytowska et al., 2023). They reported significant improvements in tests of ambulatory function and a downward trend, though not significant, in inflammatory marker C-reactive protein, in the group that received vitamin D supplementation for 12 weeks. As demonstrated in a recent review, C-reactive protein is a robust marker of inflammation in PD (Mehta et al., 2023). Given the potential benefits of vitamin D, improving vitamin D status in individuals with PD may be a valuable approach.

3.5.2. Vitamin D response to exercise

Vitamin D levels increase acutely after exercise, and these changes are further dependent on intensity of exercise, age, and sex (Maimoun et al., 2009; Sun et al., 2017; Dzik et al., 2022). In their meta-analysis, Zhang and Cao report that in most studies with chronic exercise (multiple sessions per week for >12 weeks), there is an increase in 25(OH)D in vitamin D-deficient individuals but not in vitamin-D sufficient individuals (Zhang and Cao, 2022). This positive effect has been more commonly reported in studies of endurance exercise, possibly due to lipolytic processes leading to release of vitamin D stored in adipose tissues. Exercise can also increase vitamin D receptor mRNA levels (Aly et al., 2016; Puangthong et al., 2021). Da Costa et al. report that vitamin D receptor expression is decreased in hemiparkinsonian rats, but this effect is attenuated with treadmill exercise (da Costa et al., 2022). Furthermore, they demonstrated that administering vitamin D3 with exercise improved behavioral outcomes, augmented dopamine levels, and rescued dopaminergic neurons as compared to exercise alone.

4. Discussion

We have selected and discussed a group of five hormones with links to PD and have highlighted their role in maintaining homeostasis and longevity and their responsiveness to exercise. These documented neuroendocrine abnormalities are important for several reasons: (1) increased or decreased levels of these hormones associate with various NMS of PD, such as mood, cognition, and sleep/circadian rhythm disorder in addition to classic motor symptoms, (2) these hormones act on pathways implicated in PD pathogenesis, including neuroinflammation, oxidative stress, and neurodegeneration, (3) these hormones may provide a mechanistic pathway for exercise-induced neuromodulatory effects and (4) these hormones may represent important biomarkers to measure exercise effects in clinical trials. Future studies are needed to confirm that these hormones respond to exercise specifically in individuals with PD and affect symptoms or disease progression. These insights might also help people with PD to feel empowered that they have some control over their disease if provided with evidence that regulation of these hormones has an impact on their condition (Table 1).

TABLE 1

Table 1. Exercise effects on neuroendocrine targets.

While there is a general consensus that exercise has vast benefits and should be recommended to people, the type and intensity of the exercise prescription is not always clear. Measuring biomarkers, such as the neuroendocrine targets described here, can provide objective data to compare the effects of different modalities, frequencies, and intensities of exercise. The effects of exercise may also vary with disease stage or subtype of PD and these variables need to be considered in future clinical trials of exercise in PD.

This perspective is limited in that it reviews the effects of exercise on PD-associated neuroendocrine abnormalities linked to aging and stress. However, there are other hormone imbalances in PD that have been reported and have been discussed elsewhere: (1) ghrelin and leptin that together regulate feeding behavior (Fiszer et al., 2010; Unger et al., 2011; Bayliss and Andrews, 2013), (2) growth hormone, luteinizing hormone, and estrogen that may explain mechanisms underlying sex differences in PD (Bonuccelli et al., 1990; Crespi, 1993; Ragonese et al., 2007; Hirohata et al., 2009; Georgiev et al., 2017; Vaidya et al., 2021), and (3) emerging hormones such as irisin, which can cross the blood brain barrier and has been shown to reduce pathological α-synuclein and rescue dopaminergic neurons from degeneration (Zarbakhsh et al., 2019; Kam et al., 2022; Zhang et al., 2023). Lastly, while neuroendocrine is one system that is affected in PD and responds to exercise, it is beyond the scope of this review to discuss other important systems such as neurotrophic factors and inflammatory markers that also respond robustly to exercise.

There is strong evidence-based rationale for the recommendation of regular exercise as a symptom-modifying, and possibly disease-attenuating, treatment in PD. Evolving data further supports exercise-induced changes in biomarkers but additional clinical studies are needed to link changes in these biomarkers to observed benefits in people with PD.

5. Conclusion

We conclude that exercise leads to neuroendocrine normalization with potential neuroprotective effects relevant to PD. Collectively these hormones are involved in critical functions such as maintaining homesostasis and responding to stress, sleep and circadian rhythm, insulin sensitivity, longevity, and brain health. Instead of targeting each neuroendocrine abnormality specifically, exercise provides an advantage in that it can regulate multiple hormones and thus lead to improvement in motor and non-motor symptoms and potentially slow progression of disease.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

NL: design, execution, writing, and editing of the final version of the manuscript. DCh: writing and editing of the final version of the manuscript. AC: execution, writing, and editing of the final version of the manuscript. DCo: design, execution, and editing of the final version of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Numbers U01NS113851 and K23NS123506. Research is also supported by the National Institutes of Health’s National Center for Advancing Translational Sciences, Grant Number UL1TR001422. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The research is also supported by a generous philanthropic gift in honor of Howard Gilbert.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Ali, M., Sung, Y. J., Wang, F., Fernandez, M. V., Morris, J. C., Fagan, A. M., et al. (2022). Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of klotho heterozygosity on disease risk. PLoS One 17:e0267298. doi: 10.1371/journal.pone.0267298

Aly, Y. E., Abdou, A. S., Rashad, M. M., and Nassef, M. M. (2016). Effect of exercise on serum vitamin D and tissue vitamin D receptors in experimentally induced type 2 diabetes mellitus. J. Adv. Res. 7, 671–679. doi: 10.1016/j.jare.2016.07.001

Amara, A. W., Chahine, L., Seedorff, N., Caspell-Garcia, C. J., Coffey, C., Simuni, T., et al. (2019). Self-reported physical activity levels and clinical progression in early Parkinson's disease. Parkinsonism Relat. Disord. 61, 118–125. doi: 10.1016/j.parkreldis.2018.11.006

Amaro-Gahete, F. J., de La, O. A., Jurado-Fasoli, L., Gutierrez, A., Ruiz, J. R., and Castillo, M. J. (2019). Association of physical activity and fitness with S-klotho plasma levels in middle-aged sedentary adults: the FIT-AGEING study. Maturitas 123, 25–31. doi: 10.1016/j.maturitas.2019.02.001

Amaro-Gahete, F. J., De-la, O. A., Jurado-Fasoli, L., Espuch-Oliver, A., de Haro, T., Gutierrez, A., et al. (2019). Exercise training increases the S-klotho plasma levels in sedentary middle-aged adults: a randomised controlled trial. The FIT-AGEING study. J. Sports Sci. 37, 2175–2183. doi: 10.1080/02640414.2019.1626048

Anderson, T., Vrshek-Schallhorn, S., Adams, W. M., Goldfarb, A. H., and Wideman, L. (2023). The effect of acute exercise on the cortisol awakening response. Eur. J. Appl. Physiol. 123, 1027–1039. doi: 10.1007/s00421-023-05132-4

Arking, D. E., Atzmon, G., Arking, A., Barzilai, N., and Dietz, H. C. (2005). Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ. Res. 96, 412–418. doi: 10.1161/01.RES.0000157171.04054.30

Arking, D. E., Krebsova, A., Macek, M. Sr., Macek, M. Jr., Arking, A., Mian, I. S., et al. (2002). Association of human aging with a functional variant of klotho. Proc. Natl. Acad. Sci. U. S. A. 99, 856–861. doi: 10.1073/pnas.022484299

Baker, L. D., Frank, L. L., Foster-Schubert, K., Green, P. S., Wilkinson, C. W., McTiernan, A., et al. (2010). Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch. Neurol. 67, 71–79. doi: 10.1001/archneurol.2009.307

Baluchnejadmojarad, T., Eftekhari, S. M., Jamali-Raeufy, N., Haghani, S., Zeinali, H., and Roghani, M. (2017). The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: involvement of PKA/CaMKII/CREB signaling. Exp. Gerontol. 100, 70–76. doi: 10.1016/j.exger.2017.10.023

Bassani, T. B., Gradowski, R. W., Zaminelli, T., Barbiero, J. K., Santiago, R. M., Boschen, S. L., et al. (2014). Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats. Brain Res. 1593, 95–105. doi: 10.1016/j.brainres.2014.09.068

Bayliss, J. A., and Andrews, Z. B. (2013). Ghrelin is neuroprotective in Parkinson's disease: molecular mechanisms of metabolic neuroprotection. Ther. Adv. Endocrinol. Metab. 4, 25–36. doi: 10.1177/2042018813479645

Bayo-Olugbami, A., Nafiu, A. B., Amin, A., Ogundele, O. M., Lee, C. C., and Owoyele, B. V. (2022). Vitamin D attenuated 6-OHDA-induced behavioural deficits, dopamine dysmetabolism, oxidative stress, and neuro-inflammation in mice. Nutr. Neurosci. 25, 823–834. doi: 10.1080/1028415X.2020.1815331

Belloy, M. E., Napolioni, V., Han, S. S., Le Guen, Y., and Greicius, M. D. (2020). Alzheimer's disease neuroimaging I. Association of Klotho-VS heterozygosity with risk of Alzheimer disease in individuals who carry APOE4. JAMA Neurol. 77, 849–862. doi: 10.1001/jamaneurol.2020.0414

Beserra, A. H. N., Kameda, P., Deslandes, A. C., Schuch, F. B., Laks, J., and Moraes, H. S. (2018). Can physical exercise modulate cortisol level in subjects with depression? A systematic review and meta-analysis. Trends Psychiatry Psychother. 40, 360–368. doi: 10.1590/2237-6089-2017-0155

Blume, C., Garbazza, C., and Spitschan, M. (2019). Effects of light on human circadian rhythms, sleep and mood. Somnologie 23, 147–156. doi: 10.1007/s11818-019-00215-x

Boeve, B. F., Silber, M. H., Ferman, T. J., Lucas, J. A., and Parisi, J. E. (2001). Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov. Disord. 16, 622–630. doi: 10.1002/mds.1120

Bonuccelli, U., Piccini, P., Napolitano, A., Cagnacci, A., Paoletti, A. M., Melis, G. B., et al. (1990). Reduced luteinizing hormone secretion in women with Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 2, 225–231. doi: 10.1007/BF02257653

Borghouts, L. B., and Keizer, H. A. (2000). Exercise and insulin sensitivity: a review. Int. J. Sports Med. 21, 1–12. doi: 10.1055/s-2000-8847

Brakedal, B., Flones, I., Reiter, S. F., Torkildsen, O., Dolle, C., Assmus, J., et al. (2017). Glitazone use associated with reduced risk of Parkinson's disease. Mov. Disord. 32, 1594–1599. doi: 10.1002/mds.27128

Brauer, R., Wei, L., Ma, T., Athauda, D., Girges, C., Vijiaratnam, N., et al. (2020). Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes. Brain 143, 3067–3076. doi: 10.1093/brain/awaa262

Breen, D. P., Nombela, C., Vuono, R., Jones, P. S., Fisher, K., Burn, D. J., et al. (2016). Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. Mov. Disord. 31, 1062–1066. doi: 10.1002/mds.26592

Breen, D. P., Vuono, R., Nawarathna, U., Fisher, K., Shneerson, J. M., Reddy, A. B., et al. (2014). Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. 71, 589–595. doi: 10.1001/jamaneurol.2014.65

Buxton, O. M., L'Hermite-Baleriaux, M., Hirschfeld, U., and Cauter, E. (1997). Acute and delayed effects of exercise on human melatonin secretion. J. Biol. Rhythm. 12, 568–574. doi: 10.1177/074873049701200611

Bytowska, Z. K., Korewo-Labelle, D., Berezka, P., Kowalski, K., Przewlocka, K., Libionka, W., et al. (2023). Effect of 12-week BMI-based vitamin D (3) supplementation in Parkinson's disease with deep brain stimulation on physical performance, inflammation, and vitamin D metabolites. Int. J. Mol. Sci. 24:10200. doi: 10.3390/ijms241210200

Cajochen, C., Krauchi, K., and Wirz-Justice, A. (2003). Role of melatonin in the regulation of human circadian rhythms and sleep. J. Neuroendocrinol. 15, 432–437. doi: 10.1046/j.1365-2826.2003.00989.x

Caplin, A., Chen, F. S., Beauchamp, M. R., and Puterman, E. (2021). The effects of exercise intensity on the cortisol response to a subsequent acute psychosocial stressor. Psychoneuroendocrinology 131:105336. doi: 10.1016/j.psyneuen.2021.105336

Cardinali, D. P. (2021). Melatonin and healthy aging. Vitam. Horm. 115, 67–88. doi: 10.1016/bs.vh.2020.12.004

Cardinali, D. P., Vigo, D. E., Olivar, N., Vidal, M. F., Furio, A. M., and Brusco, L. I. (2012). Therapeutic application of melatonin in mild cognitive impairment. Am. J. Neurodegener. Dis. 1, 280–291. doi: 10.1016/bs.vh.2020.12.004

Cardoso, S., and Moreira, P. I. (2020). Antidiabetic drugs for Alzheimer's and Parkinson's diseases: repurposing insulin, metformin, and thiazolidinediones. Int. Rev. Neurobiol. 155, 37–64. doi: 10.1016/bs.irn.2020.02.010

Carlson, L. A., Pobocik, K. M., Lawrence, M. A., Brazeau, D. A., and Koch, A. J. (2019). Influence of exercise time of day on salivary melatonin responses. Int. J. Sports Physiol. Perform. 14, 351–353. doi: 10.1123/ijspp.2018-0073

Castner, S. A., Gupta, S., Wang, D., Moreno, A. J., Park, C., Chen, C., et al. (2023). Longevity factor klotho enhances cognition in aged nonhuman primates. Nat. Aging 3, 931–937. doi: 10.1038/s43587-023-00441-x

Cereda, E., Barichella, M., Cassani, E., Caccialanza, R., and Pezzoli, G. (2012). Clinical features of Parkinson disease when onset of diabetes came first: a case-control study. Neurology 78, 1507–1511. doi: 10.1212/WNL.0b013e3182553cc9

Chang, Q., Hoefs, S., van der Kemp, A. W., Topala, C. N., Bindels, R. J., and Hoenderop, J. G. (2005). The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 310, 490–493. doi: 10.1126/science.1114245

Chen, W., Cai, W., Hoover, B., and Kahn, C. R. (2022). Insulin action in the brain: cell types, circuits, and diseases. Trends Neurosci. 45, 384–400. doi: 10.1016/j.tins.2022.03.001

Combs-Miller, S. A., and Moore, E. S. (2019). Predictors of outcomes in exercisers with Parkinson disease: a two-year longitudinal cohort study. Neuro Rehab. 44, 425–432. doi: 10.3233/NRE-182641

Costa, C. M., Oliveira, G. L., Fonseca, A. C. S., Lana, R. C., Polese, J. C., and Pernambuco, A. P. (2019). Levels of cortisol and neurotrophic factor brain-derived in Parkinson's disease. Neurosci. Lett. 708:134359. doi: 10.1016/j.neulet.2019.134359

Cotman, C. W., Berchtold, N. C., and Christie, L. A. (2007). Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 30, 464–472. doi: 10.1016/j.tins.2007.06.011

Crasto, C. L., Semba, R. D., Sun, K., Cappola, A. R., Bandinelli, S., and Ferrucci, L. (2012). Relationship of low-circulating "anti-aging" klotho hormone with disability in activities of daily living among older community-dwelling adults. Rejuvenation Res. 15, 295–301. doi: 10.1089/rej.2011.1268

Crespi, F. (1993). Functional in vivo interaction between growth hormone and dopamine systems are correlated to changes in striatal somatostatin levels as detected by voltammetry. Exp. Brain Res. 94, 363–370. doi: 10.1007/BF00230196

Cullinane, P. W., de Pablo, F. E., Konig, A., Outeiro, T. F., Jaunmuktane, Z., and Warner, T. T. (2022). Type 2 diabetes and Parkinson's disease: a focused review of current concepts. Mov. Disord. 38, 162–177. doi: 10.1002/mds.29298

da Costa, R. O., Gadelha-Filho, C. V. J., de Aquino, P. E. A., Lima, L. A. R., de Lucena, J. D., Ribeiro, W. L. C., et al. (2022). Vitamin D (VD3) intensifies the effects of exercise and prevents alterations of behavior, brain oxidative stress, and neuroinflammation, in hemiparkinsonian rats. Neurochem. Res. 48, 142–160. doi: 10.1007/s11064-022-03728-4

Dibner, C., Schibler, U., and Albrecht, U. (2010). The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu. Rev. Physiol. 72, 517–549. doi: 10.1146/annurev-physiol-021909-135821

Djamshidian, A., O'Sullivan, S. S., Papadopoulos, A., Bassett, P., Shaw, K., Averbeck, B. B., et al. (2011). Salivary cortisol levels in Parkinson's disease and its correlation to risk behaviour. J. Neurol. Neurosurg. Psychiatry 82, 1107–1111. doi: 10.1136/jnnp.2011.245746

Dote-Montero, M., Carneiro-Barrera, A., Martinez-Vizcaino, V., Ruiz, J. R., and Amaro-Gahete, F. J. (2021). Acute effect of HIIT on testosterone and cortisol levels in healthy individuals: a systematic review and meta-analysis. Scand. J. Med. Sci. Sports 31, 1722–1744. doi: 10.1111/sms.13999

Dubal, D. B., Yokoyama, J. S., Zhu, L., Broestl, L., Worden, K., Wang, D., et al. (2014). Life extension factor klotho enhances cognition. Cell Rep. 7, 1065–1076. doi: 10.1016/j.celrep.2014.03.076

Dubal, D. B., Zhu, L., Sanchez, P. E., Worden, K., Broestl, L., Johnson, E., et al. (2015). Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice. J. Neurosci. 35, 2358–2371. doi: 10.1523/JNEUROSCI.5791-12.2015

Duzel, E., van Praag, H., and Sendtner, M. (2016). Can physical exercise in old age improve memory and hippocampal function? Brain 139, 662–673. doi: 10.1093/brain/awv407

Dzik, K. P., Grzywacz, T., Luszczyk, M., Kujach, S., Flis, D. J., and Kaczor, J. J. (2022). Single bout of exercise triggers the increase of vitamin D blood concentration in adolescent trained boys: a pilot study. Sci. Rep. 12:1825. doi: 10.1038/s41598-022-05783-x

Eastman, C. I., Hoese, E. K., Youngstedt, S. D., and Liu, L. (1995). Phase-shifting human circadian rhythms with exercise during the night shift. Physiol. Behav. 58, 1287–1291. doi: 10.1016/0031-9384(95)02031-4

El-Sayes, J., Harasym, D., Turco, C. V., Locke, M. B., and Nelson, A. J. (2019). Exercise-induced neuroplasticity: a mechanistic model and prospects for promoting plasticity. Neuroscientist 25, 65–85. doi: 10.1177/1073858418771538

Erben, R. G. (2018). Alpha-Klotho's effects on mineral homeostasis are fibroblast growth factor-23 dependent. Curr. Opin. Nephrol. Hypertens. 27, 229–235. doi: 10.1097/MNH.0000000000000415

Esposito, E., and Cuzzocrea, S. (2010). Antiinflammatory activity of melatonin in central nervous system. Curr. Neuropharmacol. 8, 228–242. doi: 10.2174/157015910792246155

Evatt, M. L., Delong, M. R., Khazai, N., Rosen, A., Triche, S., and Tangpricha, V. (2008). Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch. Neurol. 65, 1348–1352. doi: 10.1001/archneur.65.10.1348

Evatt, M. L., DeLong, M. R., Kumari, M., Auinger, P., McDermott, M. P., Tangpricha, V., et al. (2011). High prevalence of hypovitaminosis D status in patients with early Parkinson disease. Arch. Neurol. 68, 314–319. doi: 10.1001/archneurol.2011.30

Eyles, D. W., Smith, S., Kinobe, R., Hewison, M., and McGrath, J. J. (2005). Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J. Chem. Neuroanat. 29, 21–30. doi: 10.1016/j.jchemneu.2004.08.006

Figlewicz, D. P., Evans, S. B., Murphy, J., Hoen, M., and Baskin, D. G. (2003). Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res. 964, 107–115. doi: 10.1016/S0006-8993(02)04087-8

Fiszer, U., Michalowska, M., Baranowska, B., Wolinska-Witort, E., Jeske, W., Jethon, M., et al. (2010). Leptin and ghrelin concentrations and weight loss in Parkinson's disease. Acta Neurol. Scand. 121, 230–236. doi: 10.1111/j.1600-0404.2009.01185.x

Furio, A. M., Brusco, L. I., and Cardinali, D. P. (2007). Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J. Pineal Res. 43, 404–409. doi: 10.1111/j.1600-079X.2007.00491.x

Georgiev, D., Hamberg, K., Hariz, M., Forsgren, L., and Hariz, G. M. (2017). Gender differences in Parkinson's disease: a clinical perspective. Acta Neurol. Scand. 136, 570–584. doi: 10.1111/ane.12796

Ghasemi, R., Haeri, A., Dargahi, L., Mohamed, Z., and Ahmadiani, A. (2013). Insulin in the brain: sources, localization and functions. Mol. Neurobiol. 47, 145–171. doi: 10.1007/s12035-012-8339-9

Gutierrez-Valdez, A. L., Anaya-Martinez, V., Ordonez-Librado, J. L., Garcia-Ruiz, R., Torres-Esquivel, C., Moreno-Rivera, M., et al. (2012). Effect of chronic L-dopa or melatonin treatments after dopamine deafferentation in rats: dyskinesia, motor performance, and cytological analysis. ISRN Neurol. 2012:360379. doi: 10.5402/2012/360379

Hackney, A. C. (2006). Stress and the neuroendocrine system: the role of exercise as a stressor and modifier of stress. Expert. Rev. Endocrinol. Metab. 1, 783–792. doi: 10.1586/17446651.1.6.783

Haglin, L., and Backman, L. (2016). Covariation between plasma phosphate and daytime cortisol in early Parkinson's disease. Brain Behav. 6:e00556. doi: 10.1002/brb3.556

Hartmann, A., Veldhuis, J. D., Deuschle, M., Standhardt, H., and Heuser, I. (1997). Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol. Aging 18, 285–289. doi: 10.1016/S0197-4580(97)80309-0

Hirohata, M., Ono, K., Morinaga, A., Ikeda, T., and Yamada, M. (2009). Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro. Exp. Neurol. 217, 434–439. doi: 10.1016/j.expneurol.2009.03.003

Honkala, S. M., Johansson, J., Motiani, K. K., Eskelinen, J. J., Virtanen, K. A., Loyttyniemi, E., et al. (2018). Short-term interval training alters brain glucose metabolism in subjects with insulin resistance. J. Cereb. Blood Flow Metab. 38, 1828–1838. doi: 10.1177/0271678X17734998

Hou, L., Chen, W., Liu, X., Qiao, D., and Zhou, F. M. (2017). Exercise-induced neuroprotection of the nigrostriatal dopamine system in Parkinson's disease. Front. Aging Neurosci. 9:358. doi: 10.3389/fnagi.2017.00358

Huang, C. L., and Moe, O. W. (2011). Klotho: a novel regulator of calcium and phosphorus homeostasis. Pflugers Arch. 462, 185–193. doi: 10.1007/s00424-011-0950-5

Hum, J. M., O'Bryan, L., Smith, R. C., and White, K. E. (2017). Novel functions of circulating klotho. Bone 100, 36–40. doi: 10.1016/j.bone.2016.11.025

Iranzo, A., Molinuevo, J. L., Santamaria, J., Serradell, M., Marti, M. J., Valldeoriola, F., et al. (2006). Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol. 5, 572–577. doi: 10.1016/S1474-4422(06)70476-8

Iranzo, A., Tolosa, E., Gelpi, E., Molinuevo, J. L., Valldeoriola, F., Serradell, M., et al. (2013). Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 12, 443–453. doi: 10.1016/S1474-4422(13)70056-5

Jean-Louis, G., von Gizycki, H., and Zizi, F. (1998). Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. J. Pineal Res. 25, 177–183. doi: 10.1111/j.1600-079X.1998.tb00557.x

Jeong, J. H., Koo, J. H., Cho, J. Y., and Kang, E. B. (2018). Neuroprotective effect of treadmill exercise against blunted brain insulin signaling, NADPH oxidase, and tau hyperphosphorylation in rats fed a high-fat diet. Brain Res. Bull. 142, 374–383. doi: 10.1016/j.brainresbull.2018.08.001

Jeong, J. K., Moon, M. H., Lee, Y. J., Seol, J. W., and Park, S. Y. (2012). Melatonin-induced autophagy protects against human prion protein-mediated neurotoxicity. J. Pineal Res. 53, 138–146. doi: 10.1111/j.1600-079X.2012.00980.x

Ji, N., Luan, J., Hu, F., Zhao, Y., Lv, B., Wang, W., et al. (2018). Aerobic exercise-stimulated klotho upregulation extends life span by attenuating the excess production of reactive oxygen species in the brain and kidney. Exp. Ther. Med. 16, 3511–3517. doi: 10.3892/etm.2018.6597

Jin, Z., Zhang, Z., Ke, J., Wang, Y., and Wu, H. (2021). Exercise-linked Irisin prevents mortality and enhances cognition in a mice model of cerebral ischemia by regulating klotho expression. Oxidative Med. Cell. Longev. 2021:1697070. doi: 10.1155/2021/1697070

Kalia, L. V., and Lang, A. E. (2015). Parkinson's disease. Lancet 386, 896–912. doi: 10.1016/S0140-6736(14)61393-3

Kam, T. I., Park, H., Chou, S. C., Van Vranken, J. G., Mittenbuhler, M. J., Kim, H., et al. (2022). Amelioration of pathologic alpha-synuclein-induced Parkinson's disease by irisin. Proc. Natl. Acad. Sci. U. S. A. 119:e2204835119. doi: 10.1073/pnas.2204835119

Kao, S. Y. (2009). Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors. Biochem. Biophys. Res. Commun. 385, 434–438. doi: 10.1016/j.bbrc.2009.05.089

Kim, Y. S., Joo, W. S., Jin, B. K., Cho, Y. H., Baik, H. H., and Park, C. W. (1998). Melatonin protects 6-OHDA-induced neuronal death of nigrostriatal dopaminergic system. Neuroreport 9, 2387–2390. doi: 10.1097/00001756-199807130-00043

Kim, H.-J., and Kim, D.-H. (2014). Effect of different exercise intensity on blood melatonin density in sleep disordered rats. J. Korean Soc. Phys. Med. 0, 45–53. doi: 10.13066/kspm.2014.9.1.45

Kosakai, A., Ito, D., Nihei, Y., Yamashita, S., Okada, Y., Takahashi, K., et al. (2011). Degeneration of mesencephalic dopaminergic neurons in klotho mouse related to vitamin D exposure. Brain Res. 1382, 109–117. doi: 10.1016/j.brainres.2011.01.056

Kotagal, V., Albin, R. L., Muller, M. L., Koeppe, R. A., Frey, K. A., and Bohnen, N. I. (2013). Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat. Disord. 19, 522–526. doi: 10.1016/j.parkreldis.2013.01.016

Kudo, T., Loh, D. H., Truong, D., Wu, Y., and Colwell, C. S. (2011). Circadian dysfunction in a mouse model of Parkinson's disease. Exp. Neurol. 232, 66–75. doi: 10.1016/j.expneurol.2011.08.003

Kullmann, S., Goj, T., Veit, R., Fritsche, L., Wagner, L., Schneeweiss, P., et al. (2022). Exercise restores brain insulin sensitivity in sedentary adults who are overweight and obese. JCI Insight 7. doi: 10.1172/jci.insight.161498

Kundu, P., Zimmerman, B., Quinn, J. F., Kaye, J., Mattek, N., Westaway, S. K., et al. (2022). Serum levels of alpha-klotho are correlated with cerebrospinal fluid levels and predict measures of cognitive function. J. Alzheimers Dis. 86, 1471–1481. doi: 10.3233/JAD-215719

Kunz, D., and Bes, F. (2017). Twenty years after: another case report of melatonin effects on REM sleep behavior disorder, using serial dopamine transporter imaging. Neuropsychobiology 76, 100–104. doi: 10.1159/000488893

Kuro, O. M. (2018). Molecular mechanisms underlying accelerated aging by defects in the FGF23-klotho system. Int. J. Nephrol. 2018:9679841. doi: 10.1155/2018/9679841

Kurosu, H., Yamamoto, M., Clark, J. D., Pastor, J. V., Nandi, A., Gurnani, P., et al. (2005). Suppression of aging in mice by the hormone klotho. Science 309, 1829–1833. doi: 10.1126/science.1112766

Lax, P., Zamora, S., and Madrid, J. A. (1998). Coupling effect of locomotor activity on the rat's circadian system. Am. J. Phys. 275, R580–R587. doi: 10.1152/ajpregu.1998.275.2.R580

Leon, J., Acuna-Castroviejo, D., Sainz, R. M., Mayo, J. C., Tan, D. X., and Reiter, R. J. (2004). Melatonin and mitochondrial function. Life Sci. 75, 765–790. doi: 10.1016/j.lfs.2004.03.003

Leon, J., Moreno, A. J., Garay, B. I., Chalkley, R. J., Burlingame, A. L., Wang, D., et al. (2017). Peripheral elevation of a klotho fragment enhances brain function and resilience in young, aging, and alpha-Synuclein transgenic mice. Cell Rep. 20, 1360–1371. doi: 10.1016/j.celrep.2017.07.024

Liguori, C., Fernandes, M., Cerroni, R., Ludovisi, R., Mercuri, N. B., Stefani, A., et al. (2022). Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinson's disease: a preliminary evidence. Neurol. Sci. 43, 5355–5362. doi: 10.1007/s10072-022-06111-x

Liu, H., Fergusson, M. M., Castilho, R. M., Liu, J., Cao, L., Chen, J., et al. (2007). Augmented Wnt signaling in a mammalian model of accelerated aging. Science 317, 803–806. doi: 10.1126/science.1143578

Luger, A., Deuster, P. A., Kyle, S. B., Gallucci, W. T., Montgomery, L. C., Gold, P. W., et al. (1987). Acute hypothalamic-pituitary-adrenal responses to the stress of treadmill exercise. Physiologic adaptations to physical training. N. Engl. J. Med. 316, 1309–1315. doi: 10.1056/NEJM198705213162105

Lupien, S. J., Juster, R. P., Raymond, C., and Marin, M. F. (2018). The effects of chronic stress on the human brain: from neurotoxicity, to vulnerability, to opportunity. Front. Neuroendocrinol. 49, 91–105. doi: 10.1016/j.yfrne.2018.02.001

Lupien, S. J., McEwen, B. S., Gunnar, M. R., and Heim, C. (2009). Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat. Rev. Neurosci. 10, 434–445. doi: 10.1038/nrn2639

Maimoun, L., Simar, D., Caillaud, C., Coste, O., Barbotte, E., Peruchon, E., et al. (2009). Response of calciotropic hormones and bone turnover to brisk walking according to age and fitness level. J. Sci. Med. Sport 12, 463–467. doi: 10.1016/j.jsams.2008.05.004

Malek, N., Lawton, M. A., Swallow, D. M., Grosset, K. A., Marrinan, S. L., Bajaj, N., et al. (2016). Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease. Mov. Disord. 31, 1518–1526. doi: 10.1002/mds.26698

Masso, A., Sanchez, A., Bosch, A., Gimenez-Llort, L., and Chillon, M. (2018). Secreted alpha klotho isoform protects against age-dependent memory deficits. Mol. Psychiatry 23, 1937–1947. doi: 10.1038/mp.2017.211

Matsubara, T., Miyaki, A., Akazawa, N., Choi, Y., Ra, S. G., Tanahashi, K., et al. (2014). Aerobic exercise training increases plasma klotho levels and reduces arterial stiffness in postmenopausal women. Am. J. Physiol. Heart Circ. Physiol. 306, H348–H355. doi: 10.1152/ajpheart.00429.2013

Medeiros, C. A., Carvalhedo de Bruin, P. F., Lopes, L. A., Magalhaes, M. C., de Lourdes, S. M., and de Bruin, V. M. (2007). Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J. Neurol. 254, 459–464. doi: 10.1007/s00415-006-0390-x

Mehta, N., Luthra, N. S., Corcos, D. M., and Fantuzzi, G. (2023). C-reactive protein as the biomarker of choice to monitor the effects of exercise on inflammation in Parkinson's disease. Front. Immunol. 14:1178448. doi: 10.3389/fimmu.2023.1178448

Metz, G. A. (2007). Stress as a modulator of motor system function and pathology. Rev. Neurosci. 18, 209–222. doi: 10.1515/revneuro.2007.18.3-4.209

Moffat, S. D., An, Y., Resnick, S. M., Diamond, M. P., and Ferrucci, L. (2020). Longitudinal change in cortisol levels across the adult life span. J. Gerontol. A Biol. Sci. Med. Sci. 75, 394–400. doi: 10.1093/gerona/gly279

Mohamed Ibrahim, N., Ramli, R., Koya Kutty, S., and Shah, S. A. (2018). Earlier onset of motor complications in Parkinson's patients with comorbid diabetes mellitus. Mov. Disord. 33, 1967–1968. doi: 10.1002/mds.27526

Monteiro-Junior, R. S., Cevada, T., Oliveira, B. R., Lattari, E., Portugal, E. M., Carvalho, A., et al. (2015). We need to move more: neurobiological hypotheses of physical exercise as a treatment for Parkinson's disease. Med. Hypotheses 85, 537–541. doi: 10.1016/j.mehy.2015.07.011

Moroo, I., Yamada, T., Makino, H., Tooyama, I., McGeer, P. L., McGeer, E. G., et al. (1994). Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol. 87, 343–348. doi: 10.1007/BF00313602

Muller, A. P., Gnoatto, J., Moreira, J. D., Zimmer, E. R., Haas, C. B., Lulhier, F., et al. (2011). Exercise increases insulin signaling in the hippocampus: physiological effects and pharmacological impact of intracerebroventricular insulin administration in mice. Hippocampus 21, 1082–1092. doi: 10.1002/hipo.20822

Mulvaney, C. A., Duarte, G. S., Handley, J., Evans, D. J., Menon, S., Wyse, R., et al. (2020). GLP-1 receptor agonists for Parkinson's disease. Cochrane Database Syst. Rev. 7:CD012990. doi: 10.1002/14651858.CD012990.pub2

Oguh, O., Eisenstein, A., Kwasny, M., and Simuni, T. (2014). Back to the basics: regular exercise matters in parkinson's disease: results from the National Parkinson Foundation QII registry study. Parkinsonism Relat. Disord. 20, 1221–1225. doi: 10.1016/j.parkreldis.2014.09.008

Park, S., Jang, J. S., Jun, D. W., and Hong, S. M. (2005). Exercise enhances insulin and leptin signaling in the cerebral cortex and hypothalamus during dexamethasone-induced stress in diabetic rats. Neuroendocrinology 82, 282–293. doi: 10.1159/000093127

Park, H. S., Park, S. S., Kim, C. J., Shin, M. S., and Kim, T. W. (2019). Exercise alleviates cognitive functions by enhancing hippocampal insulin Signaling and neuroplasticity in high-fat diet-induced obesity. Nutrients 11:1603. doi: 10.3390/nu11071603

Paul, K. C., Chuang, Y. H., Shih, I. F., Keener, A., Bordelon, Y., Bronstein, J. M., et al. (2019). The association between lifestyle factors and Parkinson's disease progression and mortality. Mov. Disord. 34, 58–66. doi: 10.1002/mds.27577

Peterson, A. L., Murchison, C., Zabetian, C., Leverenz, J. B., Watson, G. S., Montine, T., et al. (2013). Memory, mood, and vitamin D in persons with Parkinson's disease. J. Parkinsons Dis. 3, 547–555. doi: 10.3233/JPD-130206

Petzinger, G. M., Walsh, J. P., Akopian, G., Hogg, E., Abernathy, A., Arevalo, P., et al. (2007). Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned mouse model of basal ganglia injury. J. Neurosci. 27, 5291–5300. doi: 10.1523/JNEUROSCI.1069-07.2007

Pignolo, A., Mastrilli, S., Davi, C., Arnao, V., Aridon, P., Dos Santos Mendes, F. A., et al. (2022). Vitamin D and Parkinson's disease. Nutrients 14:6. doi: 10.3390/nu14061220

Puangthong, C., Sukhong, P., Saengnual, P., Srikuea, R., and Chanda, M. (2021). A single bout of high-intensity exercise modulates the expression of vitamin D receptor and vitamin D-metabolising enzymes in horse skeletal muscle. Equine Vet. J. 53, 796–805. doi: 10.1111/evj.13346

Ragonese, P., D'Amelio, M., Callari, G., Aiello, F., Morgante, L., and Savettieri, G. (2007). Height as a potential indicator of early life events predicting Parkinson's disease: a case-control study. Mov. Disord. 22, 2263–2267. doi: 10.1002/mds.21728

Razzaque, M. S. (2009). The FGF23-klotho axis: endocrine regulation of phosphate homeostasis. Nat. Rev. Endocrinol. 5, 611–619. doi: 10.1038/nrendo.2009.196

Rodriguez, C., Mayo, J. C., Sainz, R. M., Antolin, I., Herrera, F., Martin, V., et al. (2004). Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res. 36, 1–9. doi: 10.1046/j.1600-079X.2003.00092.x

Saghiv, M. S., Sira, D. B., Goldhammer, E., and Sagiv, M. (2017). The effects of aerobic and anaerobic exercises on circulating soluble-klotho and IGF-I in young and elderly adults and in CAD patients. J. Circ. Biomark. 6:1849454417733388. doi: 10.1177/1849454417733388

Sampath Kumar, A., Maiya, A. G., Shastry, B. A., Vaishali, K., Ravishankar, N., Hazari, A., et al. (2019). Exercise and insulin resistance in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann. Phys. Rehabil. Med. 62, 98–103. doi: 10.1016/j.rehab.2018.11.001

Sanchez, B., Relova, J. L., Gallego, R., Ben-Batalla, I., and Perez-Fernandez, R. (2009). 1, 25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum. J. Neurosci. Res. 87, 723–732. doi: 10.1002/jnr.21878

Santos-Dias, A., Mac Kenzie, B., Oliveira-Junior, M. C., Moyses, R. M., Consolim-Colombo, F. M., and Vieira, R. P. (2017). Longevity protein klotho is induced by a single bout of exercise. Br. J. Sports Med. 51, 549–550. doi: 10.1136/bjsports-2016-096139

Saper, C. B., Scammell, T. E., and Lu, J. (2005). Hypothalamic regulation of sleep and circadian rhythms. Nature 437, 1257–1263. doi: 10.1038/nature04284

Sasco, A. J., Paffenbarger, R. S. Jr., Gendre, I., and Wing, A. L. (1992). The role of physical exercise in the occurrence of Parkinson's disease. Arch. Neurol. 49, 360–365. doi: 10.1001/archneur.1992.00530280040020

Schenck, C. H., Boeve, B. F., and Mahowald, M. W. (2013). Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 14, 744–748. doi: 10.1016/j.sleep.2012.10.009

Schwarz, A. J., Brasel, J. A., Hintz, R. L., Mohan, S., and Cooper, D. M. (1996). Acute effect of brief low-and high-intensity exercise on circulating insulin-like growth factor (IGF) I, II, and IGF-binding protein-3 and its proteolysis in young healthy men. J. Clin. Endocrinol. Metab. 81, 3492–3497. doi: 10.1210/jcem.81.10.8855791

Seifried, C., Boehncke, S., Heinzmann, J., Baudrexel, S., Weise, L., Gasser, T., et al. (2013). Diurnal variation of hypothalamic function and chronic subthalamic nucleus stimulation in Parkinson's disease. Neuroendocrinology 97, 283–290. doi: 10.1159/000343808

Sekar, S., and Taghibiglou, C. (2018). Elevated nuclear phosphatase and tensin homolog (PTEN) and altered insulin signaling in substantia nigral region of patients with Parkinson's disease. Neurosci. Lett. 666, 139–143. doi: 10.1016/j.neulet.2017.12.049

Semba, R. D., Cappola, A. R., Sun, K., Bandinelli, S., Dalal, M., Crasto, C., et al. (2011). Plasma klotho and mortality risk in older community-dwelling adults. J. Gerontol. A Biol. Sci. Med. Sci. 66, 794–800. doi: 10.1093/gerona/glr058

Semba, R. D., Ferrucci, L., Sun, K., Simonsick, E., Turner, R., Miljkovic, I., et al. (2016). Low plasma klotho concentrations and decline of knee strength in older adults. J. Gerontol. A Biol. Sci. Med. Sci. 71, 103–108. doi: 10.1093/gerona/glv077

Sharma, R., McMillan, C. R., Tenn, C. C., and Niles, L. P. (2006). Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 1068, 230–236. doi: 10.1016/j.brainres.2005.10.084

Shiota, M., Sudou, M., and Ohshima, M. (1996). Using outdoor exercise to decrease jet lag in airline crewmembers. Aviat. Space Environ. Med. 67, 1155–1160.

Sieurin, J., Andel, R., Tillander, A., Valdes, E. G., Pedersen, N. L., and Wirdefeldt, K. (2018). Occupational stress and risk for Parkinson's disease: a nationwide cohort study. Mov. Disord. 33, 1456–1464. doi: 10.1002/mds.27439

Singhal, N. K., Srivastava, G., Agrawal, S., Jain, S. K., and Singh, M. P. (2012). Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation? Mol. Neurobiol. 45, 186–199. doi: 10.1007/s12035-011-8225-x

Singhal, N. K., Srivastava, G., Patel, D. K., Jain, S. K., and Singh, M. P. (2011). Melatonin or silymarin reduces maneb-and paraquat-induced Parkinson's disease phenotype in the mouse. J. Pineal Res. 50, 97–109. doi: 10.1111/j.1600-079X.2010.00819.x

Skogar, O., Fall, P. A., Hallgren, G., Lokk, J., Bringer, B., Carlsson, M., et al. (2011). Diurnal salivary cortisol concentrations in Parkinson's disease: increased total secretion and morning cortisol concentrations. Int. J. Gen. Med. 4, 561–569. doi: 10.2147/IJGM.S20875

Smith, L. K., Jadavji, N. M., Colwell, K. L., Katrina Perehudoff, S., and Metz, G. A. (2008). Stress accelerates neural degeneration and exaggerates motor symptoms in a rat model of Parkinson's disease. Eur. J. Neurosci. 27, 2133–2146. doi: 10.1111/j.1460-9568.2008.06177.x

Smyth, N., Skender, E., David, F. J., Munoz, M. J., Fantuzzi, G., Clow, A., et al. (2019). Endurance exercise reduces cortisol in Parkinson's disease with mild cognitive impairment. Mov. Disord. 34, 1238–1239. doi: 10.1002/mds.27719

Stypula, G., Kunert-Radek, J., Stepien, H., Zylinska, K., and Pawlikowski, M. (1996). Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson's disease. Neuroimmunomodulation 3, 131–134. doi: 10.1159/000097237

Sujkowski, A., Hong, L., Wessells, R. J., and Todi, S. V. (2022). The protective role of exercise against age-related neurodegeneration. Ageing Res. Rev. 74:101543. doi: 10.1016/j.arr.2021.101543

Sun, X., Cao, Z. B., Taniguchi, H., Tanisawa, K., and Higuchi, M. (2017). Effect of an acute bout of endurance exercise on serum 25(OH)D concentrations in young adults. J. Clin. Endocrinol. Metab. 102, 3937–3944. doi: 10.1210/jc.2017-00146

Suzuki, M., Yoshioka, M., Hashimoto, M., Murakami, M., Kawasaki, K., Noya, M., et al. (2012). 25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson's disease. Mov. Disord. 27, 264–271. doi: 10.1002/mds.24016

Suzuki, M., Yoshioka, M., Hashimoto, M., Murakami, M., Noya, M., Takahashi, D., et al. (2013). Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. Am. J. Clin. Nutr. 97, 1004–1013. doi: 10.3945/ajcn.112.051664

Tajiri, N., Yasuhara, T., Shingo, T., Kondo, A., Yuan, W., Kadota, T., et al. (2010). Exercise exerts neuroprotective effects on Parkinson's disease model of rats. Brain Res. 1310, 200–207. doi: 10.1016/j.brainres.2009.10.075

Takahashi, M., Yamada, T., Tooyama, I., Moroo, I., Kimura, H., Yamamoto, T., et al. (1996). Insulin receptor mRNA in the substantia nigra in Parkinson's disease. Neurosci. Lett. 204, 201–204. doi: 10.1016/0304-3940(96)12357-0

Takeuchi, N., Uchimura, N., Hashizume, Y., Mukai, M., Etoh, Y., Yamamoto, K., et al. (2001). Melatonin therapy for REM sleep behavior disorder. Psychiatry Clin. Neurosci. 55, 267–269. doi: 10.1046/j.1440-1819.2001.00854.x

Tan, S. J., Chu, M. M., Toussaint, N. D., Cai, M. M., Hewitson, T. D., and Holt, S. G. (2018). High-intensity physical exercise increases serum alpha-klotho levels in healthy volunteers. J. Circ. Biomark. 7:1849454418794582. doi: 10.1177/1849454418794582

Tillerson, J. L., Cohen, A. D., Philhower, J., Miller, G. W., Zigmond, M. J., and Schallert, T. (2001). Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J. Neurosci. 21, 4427–4435. doi: 10.1523/JNEUROSCI.21-12-04427.2001

Tolosa, E., Compta, Y., and Gaig, C. (2007). The premotor phase of Parkinson's disease. Parkinsonism Relat. Disord. 13, S2–S7. doi: 10.1016/j.parkreldis.2007.06.007

Tsujikawa, H., Kurotaki, Y., Fujimori, T., Fukuda, K., and Nabeshima, Y. (2003). Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol. Endocrinol. 17, 2393–2403. doi: 10.1210/me.2003-0048

Tuon, T., Valvassori, S. S., Lopes-Borges, J., Luciano, T., Trom, C. B., Silva, L. A., et al. (2012). Physical training exerts neuroprotective effects in the regulation of neurochemical factors in an animal model of Parkinson's disease. Neuroscience 227, 305–312. doi: 10.1016/j.neuroscience.2012.09.063

Unger, R. H. (2006). Klotho-induced insulin resistance: a blessing in disguise? Nat. Med. 12, 56–57. doi: 10.1038/nm0106-56

Unger, M. M., Moller, J. C., Mankel, K., Eggert, K. M., Bohne, K., Bodden, M., et al. (2011). Postprandial ghrelin response is reduced in patients with Parkinson's disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson's disease? J. Neurol. 258, 982–990. doi: 10.1007/s00415-010-5864-1

Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., et al. (2006). Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770–774. doi: 10.1038/nature05315

Utsugi, T., Ohno, T., Ohyama, Y., Uchiyama, T., Saito, Y., Matsumura, Y., et al. (2000). Decreased insulin production and increased insulin sensitivity in the klotho mutant mouse, a novel animal model for human aging. Metabolism 49, 1118–1123. doi: 10.1053/meta.2000.8606

Vaidya, B., Dhamija, K., Guru, P., and Sharma, S. S. (2021). Parkinson's disease in women: mechanisms underlying sex differences. Eur. J. Pharmacol. 895:173862. doi: 10.1016/j.ejphar.2021.173862

van den Heuvel, L. L., du Plessis, S., Stalder, T., Acker, D., Kirschbaum, C., Carr, J., et al. (2020). Hair glucocorticoid levels in Parkinson's disease. Psychoneuroendocrinology 117:104704. doi: 10.1016/j.psyneuen.2020.104704

Van Someren, E. J., Lijzenga, C., Mirmiran, M., and Swaab, D. F. (1997). Long-term fitness training improves the circadian rest-activity rhythm in healthy elderly males. J. Biol. Rhythm. 12, 146–156. doi: 10.1177/074873049701200206

Videnovic, A., Noble, C., Reid, K. J., Peng, J., Turek, F. W., Marconi, A., et al. (2014). Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol. 71, 463–469. doi: 10.1001/jamaneurol.2013.6239

Viho, E. M. G., Buurstede, J. C., Mahfouz, A., Koorneef, L. L., van Weert, L., Houtman, R., et al. (2019). Corticosteroid action in the brain: the potential of selective receptor modulation. Neuroendocrinology 109, 266–276. doi: 10.1159/000499659

Vlajinac, H., Sipetic, S., Marinkovic, J., Ratkov, I., Maksimovic, J., Dzoljic, E., et al. (2013). The stressful life events and Parkinson's disease: a case-control study. Stress. Health 29, 50–55. doi: 10.1002/smi.2424

Wang, C. C., Alderman, B., Wu, C. H., Chi, L., Chen, S. R., Chu, I. H., et al. (2019). Effects of acute aerobic and resistance exercise on cognitive function and salivary cortisol responses. J. Sport Exerc. Psychol. 41, 73–81. doi: 10.1123/jsep.2018-0244

Yamazaki, Y., Imura, A., Urakawa, I., Shimada, T., Murakami, J., Aono, Y., et al. (2010). Establishment of sandwich ELISA for soluble alpha-klotho measurement: age-dependent change of soluble alpha-klotho levels in healthy subjects. Biochem. Biophys. Res. Commun. 398, 513–518. doi: 10.1016/j.bbrc.2010.06.110

Yang, F., Trolle Lagerros, Y., Bellocco, R., Adami, H. O., Fang, F., Pedersen, N. L., et al. (2015). Physical activity and risk of Parkinson's disease in the Swedish National March Cohort. Brain 138, 269–275. doi: 10.1093/brain/awu323

Yokoyama, J. S., Sturm, V. E., Bonham, L. W., Klein, E., Arfanakis, K., Yu, L., et al. (2015). Variation in longevity gene KLOTHO is associated with greater cortical volumes. Ann. Clin. Transl. Neurol. 2, 215–230. doi: 10.1002/acn3.161

Zaitone, S. A., Hammad, L. N., and Farag, N. E. (2013). Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine-parkinsonian mice. Pharmacol. Rep. 65, 1213–1226. doi: 10.1016/S1734-1140(13)71479-8

Zarbakhsh, S., Safari, M., Aldaghi, M. R., Sameni, H. R., Ghahari, L., Khaleghi Lagmouj, Y., et al. (2019). Irisin protects the substantia nigra dopaminergic neurons in the rat model of Parkinson's disease. Iran. J. Basic Med. Sci. 22, 722–728. doi: 10.22038/ijbms.2019.33444.7987

Zeldich, E., Chen, C. D., Colvin, T. A., Bove-Fenderson, E. A., Liang, J., Tucker Zhou, T. B., et al. (2014). The neuroprotective effect of klotho is mediated via regulation of members of the redox system. J. Biol. Chem. 289, 24700–24715. doi: 10.1074/jbc.M114.567321

Zeng, C. Y., Yang, T. T., Zhou, H. J., Zhao, Y., Kuang, X., Duan, W., et al. (2019). Lentiviral vector-mediated overexpression of klotho in the brain improves Alzheimer's disease-like pathology and cognitive deficits in mice. Neurobiol. Aging 78, 18–28. doi: 10.1016/j.neurobiolaging.2019.02.003

Zhang, J., and Cao, Z. B. (2022). Exercise: a possibly effective way to improve vitamin d nutritional status. Nutrients 14:2652. doi: 10.3390/nu14132652

Zhang, X., Xu, S., Hu, Y., Liu, Q., Liu, C., Chai, H., et al. (2023). Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson's disease. NPJ Parkinsons Dis. 9:13. doi: 10.1038/s41531-023-00453-9

Zhou, Y. F., Luo, B. A., and Qin, L. L. (2019). The association between vitamin D deficiency and community-acquired pneumonia: a meta-analysis of observational studies. Medicine (Baltimore) 98:e17252. doi: 10.1097/MD.0000000000017252

Zigmond, M. J., Cameron, J. L., Leak, R. K., Mirnics, K., Russell, V. A., Smeyne, R. J., et al. (2009). Triggering endogenous neuroprotective processes through exercise in models of dopamine deficiency. Parkinsonism Relat. Disord. 15, S42–S45. doi: 10.1016/S1353-8020(09)70778-3

Zimmermann, M., Kohler, L., Kovarova, M., Lerche, S., Schulte, C., Wurster, I., et al. (2021). The longevity gene klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson s disease. Eur. J. Neurol. 28, 1557–1565. doi: 10.1111/ene.14733